Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Celera Genomics Reports Fourth Quarter and Fiscal 2002 Results

Rockville, MD - July 25, 2002

Celera Genomics Group (NYSE: CRA), an Applera Corporation business, today reported results for its fourth quarter and its fiscal year ended June 30, 2002. All per share amounts refer to per share of Applera Corporation-Celera Genomics Group Common Stock.

For the quarter ended June 30, 2002, Celera Genomics reported a net loss before special items of $23.1 million, or $0.33 per share, compared to $34.5 million, or $0.56 per share in the same period last year. The lower net loss was attributable primarily to the non-amortization of goodwill during fiscal 2002 and lower cost of sales and SG&A expenses. Higher development expenses within the Celera Diagnostics joint venture with Applied Biosystems and lower interest income partially offset these factors. Included in the quarter's results is a $2.8 million special charge related to the restructuring announced in June and a $6.0 million write-down of investments. Including special items, the net loss was $28.8 million, or $0.42 per share, compared with $101.7 million, or $1.66 per share, for the same quarter in fiscal 2001. Included in the fourth quarter fiscal 2001 result is a pretax special charge of $69.1 million for the impairment of goodwill and other intangible assets related to Paracel.

Revenues for the quarter increased to $28.1 million from $27.4 million for the same quarter in fiscal 2001. Online/Information Business revenue was $19.8 million, compared to $14.2 million in the same period last year. An increase in subscription revenue was offset by lower contract sequencing revenue resulting from Celera's decision not to pursue additional non-strategic service business, and the loss of revenues attributable to businesses sold earlier in fiscal 2002.

Excluding special items, Celera reported a fiscal 2002 net loss of $86.1 million, or $1.30 per share, compared to a net loss of $119.0 million, or $1.96 per share, for fiscal 2001. Special items during fiscal 2002 included a $99.0 million non-cash charge related to the acquired in-process R&D associated with the Axys acquisition, $25.9 million of special charges related to the Paracel business, and the fiscal fourth quarter 2002 items described above. Including the special items, the reported net loss for fiscal 2002 was $211.8 million, or $3.21 per share, compared with a prior year net loss of $186.2 million, or $3.07 per share. Total revenues for the fiscal year were $120.9 million, compared to $89.4 million last year. Online revenues were $72.7 million, compared to $48.4 million for fiscal year 2001. During fiscal 2002, the Group's cash and short-term investments decreased by approximately $107 million to approximately $889 million.

"Celera has concluded a challenging year of transformation with a promising preclinical pipeline, solid technology platforms, and an organization aligned with its drug discovery strategy," said Tony L. White, Applera's Chief Executive Officer. "Celera has assembled the core leadership and organization to build shareholder value and to drive future success."

"We have refined our drug discovery focus, and established a foundation on which we plan to build downstream development capabilities and a clinical portfolio. In addition, we have significantly reduced our cash burn while expanding the staff dedicated to therapeutic discovery," said Kathy Ordoņez, President, Celera Genomics. "We intend to focus on our preclinical pipeline and new target identification, and to make decisions regarding the future direction of existing unpartnered small molecule programs."

Recent Developments
Celera Genomics has reported a number of developments in its business over the last three months, including:

  • The implementation of a restructuring intended to align Celera Genomics' organization with its drug discovery and development strategy, which is based on the identification and validation of therapeutic targets from proteomics, genomics, and bioinformatics and the development of new biologics and small molecule drugs. During fiscal 2002, Celera increased the number of employees assigned to therapeutic programs from approximately 40 to 327.

  • Celera announced that Robert Booth, Ph.D. will join Celera on August 5, 2002, as Senior Vice President of Research & Development, responsible for integrating and leading all of Celera's therapeutic discovery and development activities and its R&D staff of approximately 300 people.

Online/Information Business

  • Fiscal 2002 operating income for the Online/Information Business, excluding any of the expenses of the Applera Genomics Initiative was approximately $13 million.

  • Through the introduction of its mouse SNP database, Celera Genomics demonstrated its ongoing support for the Celera Discovery SystemTM (CDS), which is now marketed exclusively through Applied Biosystems.

Celera Diagnostics Joint Venture
Celera Diagnostics is a 50/50 joint venture between Applied Biosystems and Celera Genomics that was formed in April 2001. Fiscal 2002 fourth quarter revenues for Celera Diagnostics were $2.8 million, compared to $1.6 million in the same period last year, primarily due to higher sales of its cystic fibrosis reagents. Applied Biosystems will continue to distribute Celera Diagnostics' products and record end-user sales through September 2002. End-user product sales were $3.6 million, compared to $2.0 million in the comparable year-earlier period. Net cash use was $15.2 million in the fiscal 2002 fourth quarter. The pre-tax loss for the quarter was $14.5 million, compared to $5.0 million in the same period last year.

Revenues for fiscal 2002 were $9.2 million, which corresponds to end-user product sales of $11.6 million. For fiscal 2002, the pre-tax loss was $44.7 million, and the net cash use was $45.9 million. At the conclusion of fiscal 2002, Celera Diagnostics had 173 employees.

Developments at Celera Diagnostics over the last three months include the following:

  • Celera Diagnostics and Abbott Laboratories announced an alliance to develop, manufacture and market a broad range of in vitro molecular diagnostic products for disease detection, disease progression monitoring and therapy selection. The two companies will contribute current products to the alliance and collaborate on the development of new products. Approximately 250 scientists and engineers from the two companies have been assigned to the discovery program. The alliance will focus on development of nucleic acid-based tests for infectious and genetic diseases and cancer.

  • Celera Diagnostics initiated its first disease association study in Alzheimer's disease.

  • Evaluation of new analyte specific reagents (ASRs) for cystic fibrosis testing began at selected clinical laboratories, while development proceeded on ASRs for hepatitis viral load and genotyping testing.

  • Celera Diagnostics received additional questions from the U.S. Food and Drug Administration regarding its 510(k) application to market the ViroSeqTM HIV-1 Genotyping System and expects to respond to these questions by the end of the first quarter of fiscal 2003.

Celera Genomics Outlook

  • Therapeutic programs: During fiscal 2003, Celera Genomics plans to generate and identify differentially expressed proteins in lung cancer, and to validate a number of these proteins as therapeutic targets to proceed into small molecule screening and/or antibody development. Celera also intends to initiate a second disease-specific proteomics program. In addition, Celera expects to select compounds from its existing unpartnered preclinical programs to advance internally, or through collaborations.

  • Fiscal 2003 Cash Burn: Celera Genomics' cash use is expected to decrease to between $75 and $85 million, primarily due to anticipated reductions in SG&A expenses and increased operating margin from the Online/Information Business arrangement with Applied Biosystems. Celera anticipates one-time cash receipts of approximately $20 million during fiscal 2003.

  • Fiscal 2003 Expenses: The Group anticipates R&D expenses to be in the range of $130 to $140 million. Approximately 65 percent of R&D expenses are expected to be associated with drug discovery and development activities. The discovery R&D outlook includes approximately $12 million of expenses for the Group's share of the Applera Genomics Initiative, the majority of which are expected to be incurred in the first half of fiscal 2003. This outlook does not include any potential expenses for downstream pre-clinical or clinical development programs that may be added in the future. SG&A expenses are expected to be between $30 and $35 million, at least 30 percent below fiscal 2002 levels. Pre-tax losses related to the Celera Diagnostics joint venture are expected to be approximately $50 to $60 million.

  • Fiscal 2003 Revenue: Celera Genomics anticipates total revenues between $85 and $95 million, based on its decision not to pursue new service business. Revenues from CDS subscriptions and for Knowledge Business royalties are expected to be between $75 and $80 million.

Celera Diagnostics Joint Venture Outlook

  • For fiscal 2003, Celera Diagnostics anticipates end-user sales, including those from its alliance with Abbott Laboratories, in a range of $18 to $22 million. Effective October 1, 2002, Abbott Laboratories will assume distribution from Applied Biosystems and record most end-user sales. This outlook assumes continued demand growth, both from new products and from higher sales of existing products, and successful product migration into the alliance. Celera Diagnostics plans to introduce new ASRs for cystic fibrosis and hepatitis and to complete at least three additional disease association studies. For fiscal 2003, Celera Diagnostics anticipates pretax losses of $50 to $60 million and net cash use in the range of $55 to $65 million, including capital spending of approximately $10 million.

The comments in these Outlook sections reflect management's current outlook. The Company does not have any current intention to update this outlook and plans to revisit the outlook for its businesses only once each quarter when financial results are announced.

Conference Call & Webcast
A conference call with Applera Corporation and Celera Genomics executives will be held July 25, at 10:00 a.m. (ET) with investors and media to discuss these results and management's current financial outlook for the Company. Investors, securities analysts, and representatives of the media who would like to participate should dial (+1) 706.634.4992 (code "applera") between 9:45 a.m. and 10:00 a.m. This conference call will also be webcast. Interested parties who wish to listen to the webcast should visit either and go to the Investor Relations section of the web site, or and go to the Investor section. A digital recording will be available two hours after the completion of the conference call from July 25 to August 3, 2002. Interested parties should call 706.645.9291 and enter Conference ID 4347065.

About Applera Corporation and Celera Genomics
Applera Corporation comprises two operating groups. The Celera Genomics Group, located in Rockville, MD, and South San Francisco, CA, is engaged principally in integrating advanced technologies to discover and develop new therapeutics. Celera intends to leverage its proteomic technology platform and bioinformatics capability to identify drug targets and diagnostic marker candidates, and to discover novel therapeutic candidates. Its Celera Discovery SystemTM online platform, marketed exclusively through the Knowledge Business of Applied Biosystems, is an integrated source of information based on the human genome and other biological and medical sources. The Applied Biosystems Group (NYSE:ABI) develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2002. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of novel diagnostic tests. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at, or by telephoning 800.762.6923. Information about Celera Genomics is available at

Certain statements in this press release, including the Outlook sections, are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," and "potential," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) operating losses are expected for the foreseeable future; (2) reliance on Applied Biosystems' emerging and unproven Knowledge Business for incremental revenues to Celera Genomics from the Celera Discovery System and Celera Genomics' related information assets; (3) Celera Genomics' and Celera Diagnostics' unproven ability to discover, develop, or commercialize proprietary therapeutic or diagnostic products, the risk that clinical trials of products they do discover and develop will not proceed as anticipated or may not be successful, the uncertainty that such products will not be accepted and adopted by the market, and the risk that that such products will not receive required regulatory approvals; (4) reliance on existing and future collaborations, including, in the case of Celera Diagnostics, its strategic alliance with Abbott Laboratories, which may not be successful; (5) Celera Genomics' reliance on access to biological materials and related clinical and other information, which may be in limited supply or access to which may be limited; (6) intense competition in the industries in which Celera Genomics and Celera Diagnostics operate; (7) potential product liability or other claims against Celera Genomics or Celera Diagnostics as a result of the testing or use of their products; (8) Celera Genomics' reliance on scientific and management personnel having the technical background necessary for Celera Genomics' business; (9) potential liabilities of Celera Genomics related to use of hazardous materials; (10) uncertainty of the availability of intellectual property protection and the ability to protect trade secrets, and the risk of infringement claims; (11) Celera Genomics' dependence on computer hardware, software, and Internet applications; (12) legal, ethical, and social issues which could affect demand for Celera Genomics' products; (13) risks associated with future acquisitions by Celera Genomics, including that they may be unsuccessful; (14) uncertainty of the outcome of existing stockholder litigation; (15) the possibility of delays in making Celera Diagnostics' manufacturing facility fully operational, and Celera Diagnostics' unproven ability to scale up manufacturing as products sales increase; (16) the risk that certain raw materials and equipment required by Celera Diagnostics may not be available or may not be available at acceptable prices; and (17) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

View entire press release including financial statements (.PDF file)

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.